European vs 2015-World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms

Figure 9 Prodromal polycythemia vera with normal red cell mass (red cell mass, Tables 3 and 7) and erythrocytes (< 6 × 10¹²/L, Tables 8 and 9), prefibrotic idiopathic erythrocythemia and polycythemia vera with increased erythrocytes (> 6 × 10¹²/L) and red cell mass, and evolution into masked PV with splenoegaly, spent phase polycythemia vera with myelofibrosis (Table 12) and post-polycythemia vera-myelofibrosis according to European Clinical and Pathological criteria defined by Michiels and Thiele (http://www.mpn-stichting.nl/doctors_brochure_2004.pdf) and according to the 2006-2007 World Health Organization-European Clinical Molecular and Pathological criteria for JAK2 mutated stages of prodromal overt and advanced polycythemia vera[71-73].